Form 4: Akero Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 2,380 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On June 11, 2024, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, sold 2,380 shares of Akero Therapeutics common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $22.641, with individual transactions ranging from $22.640 to $22.760.
• Following the transaction, Rolph directly owns 180,178 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sell-to-cover) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.

Stakeholder Impact

• The sale of shares by an insider could have a minor negative impact on shareholder sentiment, although sell-to-cover transactions are generally viewed as routine.

Key Dates